BeautyFarm Med, the largest provider of traditional beauty services in China Successfully Listed on the Main Board of SEHK

January 17, 2023
HONG KONG, Jan 17, 2023 - (ACN Newswire via SEAPRWire.com) - Beauty Farm Medical and Health Industry Inc. ("BeautyFarm Med" or "Company", stock code: 2373.HK), the largest provider of traditional beauty services in China in term of revenue in 2021, successfully listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today, with a board lots of 500 shares each. The stock price of BeautyFarm Med reached HK$30.5 at its debut today, representing an increase of 57.9% over the offer price. The share price closed at HK$29.65, up 53.5% and represents a market capitalization of HK$ 6.83billion.Morgan Stanley Asia Limited, Haitong International Capital Limited and Huatai Financial Holdings (Hong Kong) Limited are the Joint Sponsors to the global offering; Morgan Stanley Asia Limited, Haitong International Securities Company Limited and Huatai Financial Holdings (Hong Kong) Limited are the Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Managers to the global offering.The Company states that the listing of BeautyFarm Med in Hong Kong marks a key milestone and unfolds a new chapter in the Company's development. Looking ahead, BeautyFarm Med will strategically expand its service network and marketing channels to enlarge its client base and increase brand awareness. The Company will also further enhance its operational efficiency and client experience by introducing new technologies, equipment and products, and expanding its service offerings. Moreover, the Company will continue to cultivate, recruit and retain high-caliber talent and strengthen its human resources management mechanism; and integrate industry resources and promote the development of industry standards by deepening cooperation with upstream suppliers and sharing its industry and management experience, thereby creating greater value for the clients, shareholders and employees. Beauty Farm Medical and Health Industry Inc.Beauty Farm Medical and Health Industry Inc. (stock code: 2373.HK) is a leading player in China's beauty and health management service industry, which has a large and loyal client base, extensive network with expansion efficiency, diversified services and product offerings as well as strong brand awareness. BeautyFarm Med is the largest provider of traditional beauty services and the fourth largest non-surgical aesthetic medical service provider in China with a market share of 0.2% and 0.6%, respectively, as measured by revenue in 2021 and according to Frost & Sullivan. The Company provides overall beauty and health management services through its well-established and widely recognized brand portfolio of BeautyFarm, Palaispa, CellCare and Neology. The service offerings of the Company cover traditional beauty services, aesthetic medical services as well as subhealth assessment and intervention services, across the full client lifecycle. This press release is issued by Porda Havas International Finance Communications Group for and on behalf of Beauty Farm Medical and Health Industry Inc. For further information, please contact: Porda Havas International Finance Communications GroupTel: 852 3150 6788Email: projectgarden.hk@pordahavas.com Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More

BeautyFarm Med Announces Global Offering Results, Offer Price of HK$19.32per Share

January 13, 2023
HONG KONG, Jan 13, 2023 - (ACN Newswire via SEAPRWire.com) - Beauty Farm Medical and Health Industry Inc. ("BeautyFarm Med" or "Company", stock code: 2373.HK), the largest provider of traditional beauty services in China, today announced the allotment results of its Global Offering. The Offer Price is HK$19.32 per share. Dealings in the shares of the Company on the Main Board of the Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") are expected to commence on 16 January 2023 (Monday) with a board lot size of 500 shares.The Hong Kong Offer Shares initially offered under the Hong Kong Public Offering have been very significantly oversubscribed. A total of 6,671 valid applications have been received under the Hong Kong Public Offering through the White Form eIPO service and the CCASS EIPO service for a total of 89,670,000 Hong Kong Offer Shares, representing approximately 22.12 times of the total number of 4,054,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering. The Offer Shares initially offered under the International Offering have been moderately oversubscribed, representing approximately 4.7 times of the total number of 36,482,500 International Offer Shares initially available for subscription under the International Offering. The proceeds raised from the Global Offering of shares received by the Company are planned to be used to expand and upgrade the service network, carry out strategic mergers and acquisitions of franchise stores, and further invest in IT systems. The Company stated, through nearly three decades of deep cultivation in the industry and integration of resources, BeautyFarm Med has become a leading player in China's beauty and health management service industry. The official listing on the Hong Kong Stock Exchange marks an important milestone in the history of the development of BeautyFarm Med, opening a new chapter for the Company's development. The outstanding share oversubscription shows the trust and support of global investors for the Company's business development and lays a firm ground for the Company's long-term growth. Looking forward, BeautyFarm Med will continue strategically expanding its service network and marketing channels, introducing new technologies, equipment and products, and expanding its service offerings; continuing to cultivate, recruit and retain high-caliber talent; and integrating industry resources by deepening cooperation with upstream suppliers, thereby continuing to create greater value for the clients, shareholders and employees.Beauty Farm Medical and Health Industry Inc.Beauty Farm Medical and Health Industry Inc. (stock code: 2373.HK) is a leading player in China's beauty and health management service industry, which has a large and loyal client base, extensive network with expansion efficiency, diversified services and product offerings as well as strong brand awareness. BeautyFarm Med is the largest provider of traditional beauty services and the fourth largest non-surgical aesthetic medical service provider in China with a market share of 0.2% and 0.6%, respectively, as measured by revenue in 2021 and according to Frost & Sullivan. The Company provides overall beauty and health management services through its well-established and widely recognized brand portfolio of BeautyFarm, Palaispa, CellCare and Neology. The service offerings of the Company cover traditional beauty services, aesthetic medical services as well as subhealth assessment and intervention services, across the full client lifecycle. This press release is issued by Porda Havas International Finance Communications Group for and on behalf of Beauty Farm Medical and Health Industry Inc. For further information, please contact: Porda Havas International Finance Communications GroupTelephone: 852 3150 6788Email: projectgarden.hk@pordahavas.com Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More

Beauty Farm Medical and Health Industry Inc. Announces Proposed Listing on the Main Board of SEHK, Offer price at HK$19.32 per share

December 30, 2022
HONG KONG, Dec 30, 2022 - (ACN Newswire via SEAPRWire.com) - Beauty Farm Medical and Health Industry Inc. ("Beauty Farm" or "Company", stock code: 2373), the largest provider of traditional beauty services in China, today announces the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK").Beauty Farm plans to offer an aggregate of 40,536,500 Offer Shares under the Global Offering (subject to the Over-allotment Option), consisting of 36,482,500 International Offer Shares (subject to reallocation and the Over-allotment Option) and 4,054,000 Hong Kong Offer Shares (subject to reallocation), at a price of HK$19.32 per share.The Company will start its public offering in Hong Kong at 9 a.m. on 30 December, 2022 (Friday) and end at 12 noon on 6 January, 2023 (Friday). Dealings in shares on SEHK are expected to commence on 16 January 2023 (Monday), with the stock code of 2373 in board lots of 500 shares each.Morgan Stanley Asia Limited, Haitong International Capital Limited and Huatai Financial Holdings (Hong Kong) Limited are the Joint Sponsors; Morgan Stanley Asia Limited, Haitong International Securities Company Limited and Huatai Financial Holdings (Hong Kong) Limited are the Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Managers.Beauty and health management service provider with diversified brand portfolio in ChinaBeauty Farm is a leading player of the chain service brand in China's beauty and health management service industry, which has large and loyal client base, extensive network with expansion efficiency, diversified services and product offerings as well as strong brand awareness. According to Frost & Sullivan, Beauty Farm is the largest provider of traditional beauty services and the fourth largest non-surgical aesthetic medical service provider in China with a market share of 0.2% and 0.6% respectively, as measured by revenue in 2021. The Company provides overall beauty and health management services through its well-established and widely recognized brand portfolio of BeautyFarm, Palaispa, CellCare and Neology. The service offerings of the Company cover traditional beauty services, aesthetic medical services as well as subhealth assessment and intervention services, across the full client lifecycle. As of June 30, 2022, the overall service network of Beauty Farm comprised 352 stores, including 177 direct stores and 175 franchised stores. Among the direct stores, 84 stores were located in tier-one cities and 73 stores were located in new tier-one cities.Constant evolution of business model in response to market demand, offering clients overall beauty and health management servicesAs the leading chain brand in China's beauty and health management service industry, Beauty Farm has provided traditional beauty services to clients for nearly three decades. With insights into clients' increasingly diversified demand accumulated through years of services, the Company has extended its offerings by providing more sophisticated services such as aesthetic medical services since 2011. Thereafter, the Company commenced to build its subhealth assessment and intervention service capacity in 2018, in response to the rising demand of subhealth assessment and intervention services as a result of consumption upgrade and China's rising prevalence rate of subhealth status. Counting the revenue generated in 2021, traditional beauty services, aesthetic medical services, and subhealth assessment and intervention services represented 58.8%, 37.8% and 3.4% of the total revenue for the year. These service offerings of Beauty Farm complement each other and create a synergistic effect for the overall operations of the Company. The Company's long history in traditional beauty services has positioned the Company uniquely in the industry and fueled the revenue growth without significant increase in customer acquisition costs as the Company has become many members' lifelong trusted advisor on health and beauty. And 21.7% and 21.2% of members of the Company's traditional beauty services in 2021 and the six months ended June 30, 2022, respectively, purchased aesthetic medical services or subhealth assessment and intervention services, which is expected to further grow in the future. Likewise, the expansion of aesthetic medical services and subhealth assessment and intervention services can also further boost the growth of traditional beauty services going forward.Standardized services supported by digitalized platformBeauty Farm has established an integrated service platform to ensure high-quality services to its clients in a consistent manner across all stores. The digitalized platform of the Company is supported by standardized operating procedures and digital infrastructure covering stringent quality control, training system and supply chain management. The Company achieved one of the few highest service personnel annual retention rates in 2021 within the beauty and health management service industry. Among all the service personnel who have stayed with us for more than one year, they have an average of 6.1 years of retention. The standardization and digitalization of the business platform provides scale advantages across various aspects of the Company's operations that can be leveraged by its stores and service personnel. The integrated service platform is capable of consolidating and processing operational data accumulated from various systems across the store network. The Company also applies data mining and data analytics to obtain valuable insights to profile its clients' transaction patterns, consumption habits, and lifetime client value. Such tech-enabled enhancements allow the Company to customize its services according to clients' needs so as to maintain their stickiness and identify cross-selling opportunities. The platform-based operating model allows Beauty Farm to standardize various aspects of its operations to improve both client experience and the service performance of its service personnel. In addition, as the Company continues to accumulate and analyze digital information from its day-to-day business operations, the Company can further improve its operational efficiency.A large client base of active members supported by CRM systemThe comprehensive service offerings of Beauty Farm have attracted a large base of active clients, which is supported by a comprehensive client service system. In 2021, the direct stores of the Company served 77,356 active members, which was increased by 12.5% in 2020. The active members from direct stores on average made 10.8 visits (2020: 10.2 visits) and spent RMB20,832 in 2021 (2020: RMB20,151). 80.7%, 82.1%, 84.6% and 77.0% of the active members in 2019, 2020, 2021 and the six months ended June 30, 2022 made multiple purchases of the Company's services in the same period, respectively. In addition to the increasing client volume in direct stores, the franchised stores of the Company served 27,916 active members in 2021 and 22,552 active members in the six months ended June 30, 2022. Sustainable development supported by organic growth and strategic acquisitionsBeauty Farm has a proven track record of rapidly expanding its geographic footprint across China and has achieved rapid and sustainable business growth through both organic growth and strategic acquisitions. The scalability and replicability of its business is evidenced by its ability to open new stores rapidly. The Company opened 45 new direct stores from 2019 to June 30, 2022. Beauty Farm is able to ramp-up its new stores and achieve profitability efficiently. Contributed by the Company's long-term business relationship with prime shopping malls and the ability to bring strong footage to the venue, the typical lead time from the completion of site selection to store opening is approximately three months. From 2014 to June 30, 2022, a new traditional beauty service store on average achieved initial breakeven in eleven months after commencement of operation.Beauty Farm experienced a successful track record of identifying, acquiring and integrating stores into its network. The Company has completed 20 acquisitions in beauty and health management service industry from 2014 to June 30, 2022, most of which have successfully enhanced the Company's business offerings and management team. Upon the completion of integration, acquired stores typically witness improved business performance and rapid client expansion. For example, the acquisition of Palaispa shows the Company's acquisition power and capabilities in integration. Revenue generated from Palaispa members and franchisees increased from RMB102.4 million in 2017 to RMB185.7 million in 2021 at a CAGR of 16.0%. Those acquired stores were smoothly integrated into the Company's network, ensuring further synergies and value creation. Going forward, Beauty Farm will continue to identify and evaluate acquisition opportunities in high-quality stores to capture growth opportunities.The success of Beauty Farm is also attributable to its visionary and dedicated management with extensive industry experience, as well as strong shareholder support. Since 2013, CITIC PE, who has extensive experience managing and growing companies in the beauty and health management service industry, has been working closely with Beauty Farm to establish a standardized and disciplined chain business with nationwide footprint and has made important contributions to the company's strategic formulation, merger and expansion, executive recruitment, brand and design, human resources, supply chain, marketing, finance and other aspects of management improvement.Looking forward, Beauty Farm plans to carry out below key growth strategies to realize its development, including strategically expanding its service network and marketing channels to expand its client base and increase brand awareness; further enhancing its operational efficiency and client experience through standardization and digitalization of its system; improving client loyalty and fulfilling clients' evolving needs by introducing new technologies, equipment and products, and expanding its service offerings; continuing to cultivate, recruit and retain high-caliber talent and strengthen its human resources management mechanism; and integrating industry resources and promoting the development of industry standards by deepening cooperation with upstream suppliers and sharing its industry and management experience.Beauty Farm Medical and Health Industry Inc.Beauty Farm Medical and Health Industry Inc. ("Beauty Farm" or "Company", stock code: 2373) is a leading player in China's beauty and health management service industry, which has large and loyal client base, extensive network with expansion efficiency, diversified services and product offerings as well as strong brand awareness. According to Frost & Sullivan, Beauty Farm is the largest provider of traditional beauty services and the fourth largest non-surgical aesthetic medical service provider in China with a market share of 0.2% and 0.6% respectively, as measured by revenue in 2021. Leveraging 29 years of industry experience and adapting to evolving client demand, the Company provides overall beauty and health management services through its well-established and widely recognized brand portfolio of BeautyFarm, Palaispa, CellCare and Neology. The service offerings of the Company cover traditional beauty services, aesthetic medical services as well as subhealth assessment and intervention services, across the full client lifecycle. This press release is issued by Porda Havas International Finance Communications Group for and on behalf of Beauty Farm Medical and Health Industry Inc. For further information, please contact: Porda Havas International Finance Communications GroupTelephone: 852 3150 6788Email: projectgarden.hk@pordahavas.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Shonan iPark Outlines New Operational Structure to Provide Scale and Sustainable Long-Term Growth for the Ecosystem JCN Newswire

Shonan iPark Outlines New Operational Structure to Provide Scale and Sustainable Long-Term Growth for the Ecosystem

December 21, 2022
TOKYO, Dec 21, 2022 - (JCN Newswire via SEAPRWire.com) - Renewing its commitment to innovation in Japan and to Shonan Health Innovation Park ("Shonan iPark"), Takeda Pharmaceutical Company Limited ("Takeda") today announced the creation of a new company, effective April 1, 2023, together with Industrial & Infrastructure Fund Investment ("IIF") and Mitsubishi Corporation ("Mitsubishi Corp."), to manage Shonan iPark. In addition, IIF and Mitsubishi Corp. have agreed to acquire a portion of the shares of the new company and together with Takeda, will oversee operations for Shonan iPark. The companies will collaborate to execute on a shared vision to further develop Shonan iPark and the surrounding area's ecosystem in a multifaceted manner. Shonan iPark opened in April 2018 when Takeda transformed its research site into Japan's first pharma-led science park opening its doors to the world. In 2020, the assets (land and facilities) of Shonan iPark were placed in trust and the trust beneficiary rights were acquired by IIF in 2020 and 2021, but Takeda has continued to operate Shonan iPark on an outsourced basis. Since its opening, Shonan iPark has been operating its facilities and conducting open innovation promotion projects with a mission of "Building a life science ecosystem that is open to the world," and a vision of "Social implementation of innovative ideas." The number of tenants has grown from 20 at the time of opening, to more than 150 companies, universities and other organizations from a variety of fields, including pharmaceuticals, AI, and venture capital. To support its aim of further developing this life science ecosystem, Shonan iPark has decided to shift to the aforementioned new management structure. "Since its opening in April 2018, Shonan iPark has developed steadily with many players, including Takeda, the largest tenant, from academia, startups, companies, local hospital and governments," said Toshio Fujimoto, General Manager of Shonan iPark. "We have sought to create a neutral, magnetic hub, where these diverse range of players can gather, collaborate freely, and take on the challenge of creating innovation. I am confident that this shift to collaborative management of Shonan iPark between Takeda, IIF, and Mitsubishi Corp. will allow us to further develop all of our businesses, including facility management, community building, venture support, and collaboration with the local community. We will continue to build a life science ecosystem that is even more open to the world, while maintaining the foundation and momentum of Shonan iPark that we have built up to date."About Shonan Health Innovation Park (Shonan iPark)Shonan iPark is a science park founded in April 2018 by a pharmaceutical company. It convenes private and public sector organizations and academic institutions that widely range in terms of business type and scale and aims to be a space where health innovation can be accelerated. More than 2,000 employees (as of December 1, 2022) from more than 150 pharmaceutical, next-generation medicine, AI, venture capital, and government-related companies and organizations together form an ecosystem to enable such innovation. Visit our website here: www.shonan-health-innovation-park.com/en About Takeda Pharmaceutical Company Limited (Takeda)Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.For more information, visit www.takeda.com. About Industrial & Infrastructure Fund Investment Corporation (IIF)IIF was listed on the Tokyo Stock Exchange (Securities Code 3249) in October 2007 as the only J-REIT specializing in industrial properties.IIF aims to continuously increase unitholder value by investing in logistics facilities, factories, R&D facilities, and infrastructure facilities that are the foundation of all industrial activities and are expected to be used stably over the medium to long term, thereby ensuring stable earnings and steady growth of assets under management.IIF has concluded an asset management agreement with KKR Japan Realty Management (KJRM) and entrusts them with asset management operations in accordance with IIF's Articles of Incorporation and investment policy. About Mitsubishi Corporation (Mitsubishi Corp.)Mitsubishi Corp. works with its roughly 1,700 subsidiaries, affiliates and group companies to develop businesses in approximately 90 countries around the world. Spanning multiple industries and regions, these businesses are overseen by Mitsubishi Corp.'s Industry DX Group and 10 Business Groups: Natural Gas, Industrial Materials, Petroleum & Chemicals, Mineral Resources, Industrial Infrastructure, Automotive & Mobility, Food Industry, Consumer Industry, Power Solution, and Urban Development. Through joint digital (DX) and energy (EX) transformations invested in sustainability, decarbonization and digitalization, the company is now focused on leveraging its operations to address myriad challenges that stand to impact our planet's future. Inquiries: Shonan Health Innovation Park CommunicationAttn: Keitaro Shirayama, Haruka HibinoEmail: smb.iParkcommunication@takeda.com Takeda Pharmaceutical Company LimitedAttn: Akiko OgasawaraEmail: akiko.ogasawara@takeda.comPhone: +81-3-3278-2314 Industrial & Infrastructure Fund Investment CorporationAttn: Industrial Division, KJR Management (an Asset Management Company of Industrial & Infrastructure Fund Investment Corporation)Email: iif-3249.ir@kjrm.co.jp Mitsubishi CorporationAttn: Corporate Communications DepartmentPhone: +81-3-3210-2171 Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Bitcoin of Healthcare: EPILLO Is Pioneering Blockchain-based Health & Fitness Smart Wearables with a Digital Health Ecosystem SeaPRwire

Bitcoin of Healthcare: EPILLO Is Pioneering Blockchain-based Health & Fitness Smart Wearables with a Digital Health Ecosystem

November 29, 2022
New York, NY, November 28, 2022 – (SEAPRWire) – Europe based EPILLO Health Systems was formed in 2020 with an approach to enable consumers to manage their health services, medicines, physical activity, diet & lifestyle for the prevention and control of Chronic & Lifestyle-based diseases. The healthcare conglomerate takes the assistance of medical evidence, consumer behavior and medical technology based on WIPO-gazetted patents, and blockchain in making disruptive healthcare products & solutions. The core ideology of EPILLO Health Systems lies in democratization and personalisation of healthcare and fitness services while providing users with privacy and security of their health data. EPILLO group is leveraging the multifarious utilities that blockchain technology offers in primarily healthcare and fitness applications, in a bid to solve some of the major issues in healthcare through its disruptive products and services. CHRONIC DISEASES ARE MAJOR KILLER IN THE MODERN ERA The root of the healthcare problem lies in the increase of Global Chronic Disease burden on the world. Rapidly increasing burden of chronic diseases, such as cardiovascular diseases, cancers, chronic respiratory diseases and diabetes, kills 41 million people each year, equivalent to 74% of all deaths globally, according to WHO. Shockingly, 17 million of these deaths involve people under the age 70 years. While physical inactivity is a primary cause of chronic diseases, medication errors and ADEs (adverse drug events) are another leading causes of therapeutic failures and deaths, which annually claim 197,000 (approx) deaths in Europe. OUR ROOTS IN DIGITAL & CONSUMER HEALTHCARE EPILLO Health Systems OÜ focuses on consumer health and fitness with products & solutions in four (4) major segments of Health & Fitness industries: a) Health-focused Smart wearables (IOTs) b) Digital-Health & Digital Therapeutics (DTx) c) Retail Health & Medicine d) Health-food & Nutrition BIRTH OF BLOCKCHAIN-BASED SMART WEARABLES Smartwatches and wearable medical devices help people monitor their health 24/7. According to a report by Deloitte, 60% of the smartwatch users are concerned about the privacy of their data. The number of connected wearable devices worldwide have more than doubled in the space of three years, increasing from 325 million in 2016 to 722 million in 2019. In 2021, an unsecured database containing over 61 million records related to wearable technology and fitness services belonging to users managed by U.S. based GetHealth was left exposed online. It is of much interest and relevance in today’s time to present a secure, safe and anonymous data transmission and storage model. By combining the real-world inputs of smart wearable devices with the robust and secure execution framework of blockchain, EPILLO.io has built the world’s most secure smart wearable range – FitMint Wear. The Smart Device range is backed by cryptographic guarantees, as well as open new incentive mechanisms in athletics and health while improving data sharing, device security, and transparency. This first-of-its-kind blockchain-based smartwatch – Fitmint Wear Pro, aims to offer a unique approach to how we use and store our fitness and health data with wearable devices and adds engaging NFT-Gamification to level up your health & fitness journey. The companion decentralized mobile application (DAPP) will offer features like Move to Earn, NFT marketplace, Health-Fitness product marketplace, hosting your health data on-chain, decentralized finance (DeFi) and more. The DAPP will be available on Google Play and iOS store by the end of December 2022. Smartwatch-connected Health Suite on the other hand will offer Food & Medicine management for people with Chronic Diseases. The aforementioned Drug-Food Interaction management technology assists in medicine and food management for people with chronic conditions to help curb Adverse Drug Events (ADEs), low drug-adherence rates and medication errors. This WIPO-Gazetted Technology developed by EPILLO Health Systems was appraised at a valuation of $150 million by Sagacious IP, an International Consultancy, specializing in the Intellectual Property valuation spectrum. BITCOIN OF HEALTHCARE – EPILLO HEALTH TOKEN The project token – EPILLO Health Token, which is deployed on the Polygon (Ethereum Scaling Blockchain) chain with future Multichain upgrades on Binance Smart Chain, Ethereum, Solana and H7 chain will provide various utilities across the whole EPILLO Health Ecosystem to build a sustainable health and fitness economy. More popularly known as the “Bitcoin of Healthcare”, EPILLO HealToken will open access to Health Smart wearables, Secure Health data hosting, NFTs, DeFi and ambit of Health-Fitness products & services such as Health Insurance, Medical Aids, Genomics testing (DNA), Global Health Consultations, and more. IEO & SMARTWATCH PRE-BOOKING EPILLO Health has recently begun its IEO session with the Launchpad of P2B Crypto Exchange, users can purchase EPILLO Health Token with USDT, USD, BTC, ETH, and BNB at a discount of 8% from its premium listing price. Post the launchpad session sale, EPILLO Health Token will be listed on other popular exchanges in mid January, and the Token Generation Event will take place simultaneously. EPILLO Health Systems will begin pre-booking of their Blockchain based IoT smartwatch- FitMint Wear in December 2022 for an early January 2023 dispatch. To access the launchpad session please visit https://p2pb2b.com/token-sale/EPILLO-477/ To know more about the whole project, please visit www.EPILLO.io Social Links Twitter: https://twitter.com/epillo_io Whitepaper: https://epillo.io/whitepaper/ Media Contact Brand: EPILLO Contact: Media team Email: info@epillo.io Website: https://epillo.io/ SOURCE: EPILLO The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
More
The Executive Talk by ShareInvestor: Rojukiss International PCL (SET: KISS) ACN Newswire

The Executive Talk by ShareInvestor: Rojukiss International PCL (SET: KISS)

November 4, 2022
BANGKOK, Nov 4, 2022 - (ACN Newswire via SEAPRWire.com) - Rojukiss International PCL (SET: KISS) Chief Executive Officer, Ms. Worrawan Chaikamnerd provided an admirable interview regarding her business strategy under the tough timing caused by the Covid-19 pandemic and the company's core vision reflecting future growth.Rojukiss International PCL Chief Executive Officer, Ms. Worrawan Chaikamnerd1. Amid the Covid-19 pandemic, what challenges have your business faced? And what is your key strategy?The COVID-19 pandemic has been one of the major challenges for Thailand's beauty industry and our company. We must refine our strategies and business plans to cope with the ever-changing market and rapidly changing consumer behavior.Regarding the long-term strategy, we aim to increase our top line to 3,000 million baht by 2026. Our focus remains on beauty and health products, such as skincare, makeup, hair color, and food supplements, which align with the company's vision and mission: To be Asia's leading beauty and health company by creating the best innovation to fulfil everyone's demand and inspiring people across Thailand and Asia.2. How is your product development and business expansion plan?The priority is to grow and strengthen our core brand - the Rojukiss brand by enhancing the product innovation. At the same time, we continue searching for opportunities to reach consumers by adjusting marketing strategies called "Beauty Convenience." Since Q1/2022, we have been trying to communicate with consumers through digital channels and leveraging data to create effective communication. All supports from our market research team provides in-depth market insights, ensuring that we proceed with the best fit consumer-based strategy.One tactical approach we used during the pandemic was increasing product volume but maintaining the price. With this promotion, we not only added value and increased customers' access to the product but also captured profitability at a reasonable level. As a result, Rojukiss has continued to grow despite the challenging business environment amid the slow trending of Covid-19 pandemic. with a sales target of 1,000 million baht by 2024 as Rojukiss remains our powerhouse brand.In addition, we have also attempted to push other potential brands, especially "Best Korea" brand, in which we have upgraded into new formulas and imported ingredients from abroad. The brand highlights its 'convenience to carry and use anywhere' concept because we distribute it as a sachet, which also comes up with an affordable price for everyone. Furthermore, we also launched a new product under the Best Korea umbrella, "Best Korea SSUK," targeting to teen shoppers. The company is committed to build Best Korea the Second Pillar.Strengthen the company with health innovationsOur core vision and mission is to become Asia's leading beauty and health company by creating the best health-related innovation. Recently, we invested in Hibiocy Co., Ltd. (HIB) to expand our business into health innovations. Consequently, we were able to roll out the first product called "Vaill CoviTRAP Anti-CoV Nasal Spray", designed to suppress the COVID-19 virus physically. We received a very positive support from the market.Expanding markets and opportunities to become Asia's leading beauty and health companyRegarding the company's long-term plan, we also search for new growth opportunities abroad. Currently, we have entered into four major countries: Indonesia and Vietnam - through the foreign distributor model, Laos and Cambodia - through the cross-broader sale model. In these markets, we found high demand for beauty and health products and similar customer behavior to that of Thai consumers. Particularly in Indonesia, after the product kicked-off, we received an impressive receptivity that exceeded our expectations.Overall, our key strategy is to focus on developing new products, bringing out the best of Rojukiss and adjusting the products to fill the gap in consumption trends. Therefore, we must understand the consumer first, build innovative product, and find a suitable partner whose expertise could bring us into the market.3. At the end of Q3/2022, KISS launched a new product concerning COVID-19 virus prevention. Please tell us about its specialty.For this project, we collaborated with Faculty of Medicine at Chulalongkorn University, the Institute of Health Systems Research (HSRI), Silpakorn University, and the Government Pharmaceutical Organization (GPO) to form up the Thai medical working team to fight against COVID-19. Consequently, we successfully invented Thailand and the world's first innovation in developing a nasal spray with Monoclonal Human Antibody Cocktail technology from research on human immunity to combat and inhibit the COVID-19 virus. It is considered an advanced biological technology developed from decoding antibodies obtained from volunteers who have recovered from COVID-19 infection and have excellent immunity, which helps inhibit and prevent COVID-19 physically. Impressively, it could hinder the infection covering up to 98% of all species and last up to 6 hours.This nasal spray works in two functions; (1) trapping the virus with the HPMC that covers the surface of the nasal cavity, which reduces the virus's ability to embed itself in the nasal cavity, and (2) excellent immunity, adopted from recovered patients (Human Monoclonal Antibodies), will inhibit and block COVID-19 entering the nasal cavity physically.For me, this product is the pride of Thais whose breakthrough innovation could transform society. It shows our indubitable potential, which is second to none in the world.4. What core value have you and your company employees adhered to?As a beauty and health company, we have always committed to integrity, especially to our customers, partners, shareholders, and other stakeholders.Honesty and integrity mean providing valuable products that serve consumers' demands at an accessible price, as well as maintaining consistent Rojukiss grade quality.On behalf of Rojukiss International Pcl, we will continue to develop products through innovations and with latest technologies under ethical business practices and good corporate governance. All aim to orchestrate the organization to grow sustainably.Watch Executive Talk by ShareInvestor on YouTube ShareInvestor Thailand https://www.youtube.com/c/ShareInvestorThailand About The Executive Q&A SeriesThe Executive Q&A Series is presented by ShareInvestor, Asia's leading financial internet media and technology company and the largest investor relations network in the region. For more information, email admin.th@shareinvestor.com, and visit our Website: www.ShareInvestorThailand.com. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics Signs Agreement with National Institutes of Health to Explore Research Opportunities ACN Newswire

Malaysian Genomics Signs Agreement with National Institutes of Health to Explore Research Opportunities

October 12, 2022
PETALING JAYA, Malaysia, Oct 12, 2022 - (ACN Newswire via SEAPRWire.com) - MGRC Therapeutics Sdn Bhd (MGRC-T), a wholly-owned subsidiary of Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, has entered into a cooperation agreement with the National Institutes of Health, Malaysia (NIH), providing a framework for collaboration between the two parties in medical research pertaining to genomics and biopharmaceuticals.Dato' Alvin Joseph Nesakumar, Executive Director of Malaysian GenomicsThe National Institutes of Health (NIH), the research arm under the Ministry of Health Malaysia, comprises six research institutes that focus on biomedical research, public health and epidemiology, clinical research, behavioural health research, health management and health policies. The NIH is mandated to conduct high-impact health research to improve the quality of life of the Rakyat. The health research conducted by the NIH is in line with the Health Research Priority Areas for each five-yearly Malaysia Plans.MGRC-T specialises in genomics and biopharmaceutical services with proprietary know-how and intellectual property related to the research, development, and processing of genetic screening tests, as well as the manufacturing of cell therapies, including immunotherapy for various types of cancer.Dato' Alvin Joseph Nesakumar, Executive Director of Malaysian Genomics, said, "The cooperation agreement enables us to explore ways that we can work together with NIH to improve the quality of our genomics and biopharmaceutical services that can contribute to improving the health of the Rakyat. We consider this collaboration a good step in encouraging and promoting research in genomics and biopharmaceuticals that will be mutually beneficial."Dr S Asmaliza Ismail, Manager of the NIH said, "We welcome this agreement as we are keen to work with specialists such as Malaysian Genomics to exchange knowledge in various fields of medical research. We believe that by working and pooling our resources together, we can bridge the gaps in expertise and experience."Under this agreement, the parties will explore joint training in the field of medical research, exchange research materials, and partake in scientific data presentation and publication. Additionally, the agreement will enable the exchange of experts and personnel, including postgraduate research and students on adjunct appointments, short- and long-term research attachments, co-supervision of students conducting research and internships, as well as other areas of cooperation to be mutually decided.Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
ClinicalSquared Partners with Solve.Care to Create Web3 Health Networks on the Blockchain ACN Newswire

ClinicalSquared Partners with Solve.Care to Create Web3 Health Networks on the Blockchain

October 12, 2022
Washington, D.C., Oct 12, 2022 - (ACN Newswire via SEAPRWire.com) - Solve.Care (https://solve.care/), a healthcare platform company that leverages blockchain to deliver better care and ClinicalSquared (www.clinicalsquared.com), a multi-disciplinary technology consulting company specializing in custom software development, today announced that they have joined forces to create Web3 health networks on the Solve.Care Platform. The announcement was made at the Blockchain & Infrastructure Conference held at the National Press Club in Washington DC, and organized by the Government Blockchain Association.The decentralized Care.Platform from Solve.Care allows for the quick creation and deployment of interoperable health networks. Governments, businesses and even individuals can author their own networks using the Care.Labs low-code development portal. Digital health networks on the Care.Platform are known as Care.Networks. Data in Care.Networks are stored on decentralized nodes, where all interactions and transactions are automatically tokenized. They can be authored without the need for any Web3 or blockchain knowledge. Care.Network owners can also opt to outsource the authoring of their Care.Networks to any third party or utilize ClinicalSquared, having been appointed as the official authoring agent of Care.Platform. Pradeep Goel, CEO of Solve.Care said, "Having ClinicalSquared on board, enables for our clients to have their Care.Networks rolled out to the market at an even quicker timeframe. While our clients are in the best position to know when they want from their Care.Networks, they may not always have the capacity to author them. It is about giving our clients options that best serve their interests."Marquis Allen, CEO of ClinicalSquared said, "We are excited to partner with the Solve.Care team, leveraging our skills, technical resources, and formidable experience in the healthcare IT sector to accelerate the development of blockchain-featured healthcare solutions. We welcome the opportunity to serve."Both ClinicalSquared and Solve.Care are members of the Government Blockchain Association (GBA) (https://gbaglobal.org/). The GBA is an association that connects people and organizations with blockchain technology-based solutions to problems typically faced by government entities.Source: Platodata Intelligence https://platodata.io Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
EC Healthcare Acquires Multi-Disciplinary Healthcare Services Chain in Hong Kong ACN Newswire

EC Healthcare Acquires Multi-Disciplinary Healthcare Services Chain in Hong Kong

October 3, 2022
HONG KONG, Oct 3, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group and the Seller enters into a sale and purchase agreement to acquire 60% of the issued share capital of Pioneer Evolution Limited (the "Target Company") for a total consideration of HK$36.4 million in cash. The Target Company is a controlling holding company of a medical service provider which has a long-standing history in providing multi-disciplinary healthcare services in Hong Kong since 2002 and operates 9 medical centers under the business name of Sure-Care Medical and Health Network. Sure-Care Medical and Health Network has an extensive geographic coverage over Kowloon, New Territories and HK Island, including Mong Kok, Tai Po, Causeway Bay, Tsuen Wan and Jordan. Sure-Care Medical and Health Network also has a professional medical team of over 23 registered medical practitioners and covering 8 medical specialties and general medical services. According to the unaudited consolidated financial information, the profit after tax of the Target Company was approximately HK$5.9 million for the six months ended 30 June 2022 and HK$12.1 million for the year ended 31 December 2021. Upon completion of the acquisition, the financial results of the Target Company will be consolidated into the consolidated financial statements of the Group. The Seller guarantees to the Group with an accumulated net profit for the five years ending 31 December 2027 should be no less than HK$70 million. The acquisition of the multi-disciplinary healthcare services is expected to deepen the Group's medical services layout and enable the Group to further increase its market share in the healthcare market. Upon the completion of the acquisition, the Group's full time registered doctor team will be expanded and the Group's medical services capability will be further strengthened in Hong Kong, particularly in New Territory East and expected to create cross referral to increase market share. Leveraging on the Group's operational excellence and efficiencies, the Group will empower Sure-Care Medical and Health Network to improve its asset value through corporatization. Mr. Levin Lee, Executive Director and Chief Finance Officer of EC Healthcare, said, "EC Healthcare is always committed to building up an enclosed ecosystem to provide premium services to the client by leveraging multiple brands and disciplines. The acquisition is aligned with the Group's expansion strategy and will further consolidate the Group's leading market position in Hong Kong's healthcare market, maximizing overall shareholders' return. EC Healthcare will continue to be the leading market consolidator and develop its businesses through organic growth and mergers and acquisitions and strive to be the Asia leading healthcare services provider."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, an advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021For further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk / Tim Tin / Sophia Wu Tel: (852) 2136 6952 / 2169 0467 / 3920 7654 / 3920 7645Fax: (852) 3170 6606 Email: ech@iprogilvy.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Fujitsu and Tsuda University launch joint research on social design to realize sustainable, flexible community health care amidst aging society JCN Newswire

Fujitsu and Tsuda University launch joint research on social design to realize sustainable, flexible community health care amidst aging society

August 25, 2022
TOKYO, Aug 25, 2022 - (JCN Newswire via SEAPRWire.com) - Fujitsu Limited and Tsuda University today announced the launch of a social design joint research project to realize sustainable and flexible community health care services in Japan. The project aims to realize a framework to provide patients with high-quality medical and health services even with limited social resources by leveraging converging technologies: advanced technologies that combine computer sciences including AI with the humanities and social sciences such as empirical economics. The project is scheduled to commence on August 25, 2022.Image of the joint researchWithin this project, Fujitsu and Tsuda University will digitize so-called "care pathways," the flow of medical and health services that patients receive, including disease prevention, treatment, and prognosis. Leveraging Fujitsu's AI technology to predict patients' conditions on the care pathway from medical and health data (1) and Tsuda University's findings from empirical economics (2), the two parties will analyze patients' care pathways and identify bottlenecks in existing regional healthcare systems to ultimately offer patients more efficient and high-quality health services. With the cooperation of medical institutions and local governments in Japan, the two parties aim to establish a methodology to propose improvements to patients, local governments and service providers, and to build consensus for the practical implementation of these proposals in society.By the end of FY 2024, Fujitsu aims to connect people with medical institutions, companies, and governments, and apply the sustainable and highly flexible care pathway design technology developed in this joint research to help realize a more consumer-centric industry and society. Fujitsu will further conduct field trials with the goal of applying the newly developed service to a wide range of global medical and health service providers in Japan and beyond. Fujitsu will continue to promote "Healthy Living," one of its key focus areas under its global business brand Fujitsu Uvance, to create a world that enriches the life experience of everyone.An aging society: growing need for transparent, patient-centered innovationThe rapid aging of society represents an ongoing, urgent social issue in many parts of the industrialized world. In Japan, the ratio of the population aged 65 and over has reached 28.6% in recent years (3). As the aging of society continues to increase in many countries, building a sustainable service provision system that can maintain the quality of medical care and nursing care by efficiently using limited resources is developing into a major societal issue confronting the world.However, medical and health services, including those relating to disease prevention, treatment, and prognosis, are currently provided as separate services, and comprehensive coordination of these services based on a patient's condition and situation is not yet possible. Due to this lack of coordination, patients, for example, that are transferred between different hospitals, tend to feel insecure as they cannot overview their further treatment. Yet, attempts to improve the quality of medical and health services prove to be problematic, as they require a large amount of social resources and improvements often even lead to a lower efficiency in the provision of services.Within this project, the two parties will combine Fujitsu's digital technologies including an AI-based technology to predict patient conditions and a matching technology to derive fair assignments with Tsuda University's research findings from empirical economics perspectives, such as health innovation through hospital downsizing (reduction of hospital beds) and urban space realignment (4).About the joint research1. Period:August 25, 2022 - March 31, 2023 (scheduled to continue after April 1, 2023)2. Research Overview:Fujitsu and Tsuda University will conduct region-wide analysis of patients' "care pathways" (the flow of medical and health services) based on delivery systems and procedures planned by medical institutions and local governments, in combination with patients' actual medical and health data (receipt information etc.) to identify bottlenecks in current healthcare systems such as regional disparities in delivery systems and prolonged hospitalization. To identify bottlenecks, Tsuda University will analyze the problem areas by combining its accumulated knowledge in empirical economics with Fujitsu's AI technology to predict patients' conditions on the care pathway from medical and health data. To reduce the identified bottlenecks, Fujitsu and Tsuda University aim to improve both the quality of services to patients and the efficiency of service provision throughout the region. To this end, the two parties will develop a care pathway design technology to improve plans for systems and procedures for providing medical and health services that can resolve issues from the perspective of patients, local governments, and service providers in the region.To realize practical application of improvement plans for medical and health service provision systems and procedures, Fujitsu and Tsuda University will cooperate with medical institutions and local governments to establish a methodology for consensus building through solution proposals based on empirical economics.3. Roles and responsibilities:Fujitsu- Centralized visualization of patients' individual care pathways across the region and identification of bottlenecks- Development of technology to design improvement plans for care pathways based on medical and health dataTsuda University- Visualization of diseases and medical indicators such as physical functions and cost-effectiveness based on medical and health data- Proposal of policies related to regional healthcare delivery systems and setting up of forums for discussion toward consensus building- Analysis of methodologies for a balanced downsizing of healthcare facilities (reduction of hospital beds) and improvement of therapeutic efficacyFuture PlansAs part of this joint research, Fujitsu and Tsuda University will conduct verification tests using medical and health data in cooperation with Yamagata University (5) and other organizations, including hospitalization records and outpatient medical records in Japan's Yamagata Prefecture, which is promoting the establishment of a community-based healthcare system. Fujitsu and Tsuda University will apply the results of their joint research to communal heath institutes in the Yamagata Prefecture and other regions to verify the effectiveness of their newly developed system.(1) Medical and health data: Data from the DPC system ("Diagnosis Procedure Combination data", information collected and managed by the Japanese Ministry of Health, Labour and Welfare pursuant to the provisions of Paragraph 5 (iii) of the "Calculation method for the amount of expenses required for medical treatment in wards of hospitals designated by the Japanese Minister of Health, Labour and Welfare") and the KDB system ("Kokuho Database" - "The National Health Insurance Database of Japan") is used to create statistical information from benefit information (medical checkups, medical care, and nursing care) managed by the Japan Health Insurance Association through various operations, as well as data on patient health entrusted by insurers. Both data types are encrypted so that patients cannot be identified.(2) Empirical economics: An approach to economic methodology that considers empirical analysis based on economic theory.(3) The ratio of the population aged 65 and over has reached 28.6% in recent years: Statistics Bureau of Japan, News Bulletin December 28, 2021(4) Health innovation through hospital downsizing (reduction of hospital beds) and urban space realignment: By reducing hospital beds, the number of personnel will be increased to provide more intensive services to each patient. The goal is to improve health by providing comprehensive services to patients in the non-occupied space of the hospital (Research representative: Yukiko Ito, Professor, Department of Policy Studies, Tsuda University). https://www.jst.go.jp/ristex/stipolicy/project/project30.html (in Japanese)(5) Yamagata University:Main campus: Yamagata City, Yamagata Prefecture; President: Hidetoshi Tamate.About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$32 billion) for the fiscal year ended March 31, 2022 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.About Tsuda UniversityTsuda University is a private institution of higher education for women, with a history of more than 120 years since its founding. It has two colleges and the Graduate School, which are now located on two campuses in Tokyo. Since its foundation, Tsuda University has cultivated women who demonstrate leadership with their practical expertise and analytical insights grounded in solid and wide-ranging knowledge. Tsuda University has also earned an excellent reputation for producing distinguished alumnae who have contributed to society locally as well as internationally in various fields. Find out more: https://www.tsuda.ac.jp/en/. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics Explores Strategic Partnership with MAHSA Health through MoU ACN Newswire

Malaysian Genomics Explores Strategic Partnership with MAHSA Health through MoU

August 18, 2022
PETALING JAYA, Malaysia, Aug 18, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad's (Bursa: MGRC, 0155) wholly-owned subsidiary, MGRC Therapeutics Sdn. Bhd. signed a memorandum of understanding (MoU) with MAHSA Health Sdn Bhd to discuss the formation of a strategic partnership promoting practice-based education, research and knowledge exchange.En. Azri Azerai, Executive Director of Malaysian GenomicsDatin Dr Maya, Chief Executive Officer of MAHSA HealthMalaysian Genomics is the first company in Malaysia to pioneer genomics and genetic screening in Malaysia for over 17 years. Since then, Malaysian Genomics has expanded its offerings in other important areas in the healthcare and wellness that include cancer immunotherapy, cell manufacturing services and kidney dialysis. Malaysian Genomics continues to strive to provide the latest in precautionary, preventive and curative healthcare services for its local and worldwide customers.MAHSA Health Sdn Bhd is a Malaysia-grown company, part of MAHSA Group of Companies, which is determined to be a revolutionary leader in healthcare. Since its inception in 2017, MAHSA Health has been striving to be in the forefront of primary healthcare, focusing on family health and wellness.Encik Azri Azerai, Executive Directorof Malaysian Genomics said, "We look forward to sharing our experience in genomics, bioinformatics, and biopharmaceuticals with MAHSA Health via this collaboration. By providing industry inputs and insights to MAHSA, we hope to benefit students at MAHSA with the tremendous promise that various healthcare sciences have to offer for all.""Through this collaboration we also hope to identify opportunities to improve the delivery of integrated, holistic primary healthcare services, including genetic screening services to improve the lives of individuals in the long run."Datin Dr Maya, CEO of MAHSA Health, with her double expertise in health and wellness services, and education industry, said, "Passion is the greatest asset we each have. The main idea of MAHSA Health is to improve the quality of life in providing health care and wellness services to our community. We are a team-based healthcare that provides comprehensive medical care to patients with the goal of obtaining maximized health outcomes.""Through this collaboration, we foresee opportunities and collaborative efforts in many areas, both in health care and education industry in providing an ecosystem of teaching, training, and producing services to the country nationwide."The MoU is a framework through which MGRC Therapeutics and MAHSA Health can explore opportunities for health and wellness-related services; create opportunities for students' clinical placement, internship and employment; identify opportunities for conducting collaborative research and development (R&D); and create opportunities in training, seminars and conferences.Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
6th Annual ConV2X Telehealth 2022 Event Announced ACN Newswire

6th Annual ConV2X Telehealth 2022 Event Announced

August 1, 2022
North Miami, Florida , Aug 1, 2022 - (ACN Newswire via SEAPRWire.com) - The acclaimed annual telehealth event catalyzes C-suite global market executives driving the transformation of telehealth, data science, and edge technologies and includes healthcare leadership & breakthrough technology providers to inspire and guide informed decision making to successfully navigate a new digital health era.The full day event will present keynotes, panel discussions, and unparalleled business and research network opportunities.The audience includes top multidisciplinary global leaders from platform providers, health systems, payors, universities, government, NGO, consultants, think tanks, clinicians, pharmaceutical & medical device manufacturers, VCs/Investors, students and startups.Date: Thursday, October 11, 2022Time: 8 AM - 5 PM ETPlace: Florida International UniversityLocation: Biscayne Bay Campus: 3000 NE 151st St, North Miami, FL 33181Theme: Integrating Telehealth: Problems. Solutions. Future.Tickets: https://telehealth2022.conv2xsymposium.com/Participating Companies:- Health and Human Services (HHS)- NASA- WHO- Microsoft- TLGG Consulting- World Bank- Biofourmis- Vizient- Solve Care- UC Irvine Health- Cincinnati Children's Hospital- Teladoc- Jefferson Medical College- Oschner Health System- Harvard Medical Faculty Physicians- Harvard Medical School- Softhread- Navicent Health- Vivalink- AImedica- Ravkoo HealthAnd more...Topics will include:- Health System Challenges, Growth and Market Transformation- Redefining Telehealth for Long Term Resilience- Precision Healthcare, the Role of Providers and Technology- Digital Health Around the Globe: Regulation, Case Use & Success- Smart Health, Data Science, and AI- Reducing Medical Error, Duplication and Simplified Process- Learning with Digital Tools, Apps and Software- Customer Journeys and Loyalties- Information Governance And Data Protection- Workforce Training, Retention and Transformation- Market Research and Analysis- Data Science and Artificial IntelligenceEvent Sponsors: Greenberg Traurig LLPIEEE SAKenessaw UniversityFor sponsor opportunities contact:Tory Cenaj at t.cenaj@partnersindigitalhealth.comAleksandar Linc-Djordjevic at a.linc@datasciconference.comJovan Marjanovic at jovan.marjanovic@gmail.com About ConVerge2XcelerateConVerge2Xcelerate (#ConV2X) Telehealth 2022 is the undisputed leading telehealth event in the USA. The live and in person event is where service providers, health systems, payors, providers, tech, entrepreneurs and innovations collide. Thought leaders and pioneers blazing trails will share critical business insights. Forge meaningful partnerships. Be a part of this critical dialog. Lessons learned from this event will likely guide your strategic plan, impact your business, the marketplace and your personal vision for years to come. ConV2X creates an irresistible environment for telehealth executives and future leadersExperience more from the Telehealth and Medicine Today (THMT) multimedia proceedings issue at https://telehealthandmedicinetoday.com/index.php/journal. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Digital Health and Technology Trends in the USA ACN Newswire

Digital Health and Technology Trends in the USA

August 1, 2022
AUSTIN, TX, Aug 1, 2022 - (ACN Newswire via SEAPRWire.com) - What role and purpose will businesses accept to impact the social contract, and how might consumer and provider empowerment might bring change to healthcare business models using technology?The Partners in Digital Health blockchain in healthcare and telehealth portfolio both reflect and set trends in the marketplace. Here are a few trends and current issues to ponder.Cost, place, and preference have prioritized the care at home care and care transitions as aging populations and a looming healthcare worker shortage impact the US health system, where virtual care presents an opportunity to build long term resilience into system.Adopting Zero Trust Architecture to enhance security across agencies and businesses must quickly be adopted, following the executive order on improving the Nation's Cybersecurity (EO 14208). If you've been hacked recently, you understand the urgency.A fully realized digital 3D world (Web3/Metaverse), creating virtual holographic experiences, including digital twins that operate in real-time, must be created for secure use. Healthcare is at the forefront with medical education initiatives and holoportation. Ambient AI, or real-time human perception technology, that enables intelligent environments is an area where technology can anticipate and respond to people's needs, customize and forecast behaviors across the continuum of care - and reduce the cost of care. Compliant AI-powered conversational patient intake can also increases time and quality time engagement with patients.Diversity and inclusion present new market opportunities for drug discovery, startups, apps, payment models, cross boarder collaborations, market investment and more. Pandemics teach us there are significant differences in patient populations with sexual, cultural, age, and geographic diversities to consider.The cash economy in healthcare is on the rise. A retail health revolution is occurring where employers give their employees cash instead of health insurance. Consumers pay cash for drugs and services that are cheaper than those covered through insurance - and participants don't have to deal with system bureaucracy.Price transparency for health insurance market plans to make hospital pricing transparent for patients to compare costs for care is embraced by 85% of Americans. Consumers believe cost cutting and improving quality through transparency should be a priority. Site neutral payments are another way to level the playing field and could save the USA as much as $350 billion over the next decade.Cryptography and applying quantum mechanics for uncrackable code for two parties to interact securely. The US is teetering on losing its competitive edge and may have already. Blockchain will improve how the public interacts with government services and will have broad economic and social implications. Global health passes and interoperable permissioned global networks are examples and only the beginning of the wave impacting healthcare.At ConV2X, just about every facet of blockchain technology is explored including cybersecurity and quantum computing, patient experiences, credentialing, data ownership, Metaverse, NFTs, DAOs, TradFi, privacy protection, joint workflows and processes, inventory management, fraud, chargebacks, precision medicine, zero trust frameworks, standards and more.A real revolution of borderless interoperability, led by consumers, activists and pioneers, challenging market integrity and sensibilities is well underway.For more information visitBlockchain in Healthcare Today (https://blockchainhealthcaretoday.com/index.php/journal) journal, or ConV2X Blockchain in Healthcare 2022 (https://conv2xsymposium.com/registration/) eventTelehealth and Medicine Today (https://telehealthandmedicinetoday.com/index.php/journal) journal, or ConV2X Telehealth 2022 (https://telehealth2022.conv2xsymposium.com) event Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Hitachi: Proton Therapy Provider Chosen for UW Health Eastpark Medical Center JCN Newswire

Hitachi: Proton Therapy Provider Chosen for UW Health Eastpark Medical Center

July 27, 2022
MADISON, WI, Jul 27, 2022 - (JCN Newswire via SEAPRWire.com) - UW Health has selected Hitachi, Ltd. (TSE:6501, "Hitachi") to provide the infrastructure to support proton therapy at UW Health Eastpark Medical Center.Proton therapy equipment combined with Hitachi's 360° rotating gantry and Leo's upright systemHitachi will provide equipment and technology to support UW Health's traditional proton therapy room equipped with spot scanning irradiation technology, a 360 degrees rotating gantry with cone-beam CT(1), and Real-time image Gated Proton Therapy (RGPT)(2), as well as the revolutionary upright proton therapy coming to UW Health from Leo Cancer Care, according to Dr. Paul Harari, radiation oncologist, UW Health, and chair of the Department of Human Oncology, University of Wisconsin School of Medicine and Public Health."We're excited to reach this important milestone to offer state-of-the-art proton therapy at UW Health," Harari said. "It's particularly significant in linking together Hitachi, an experienced proton provider, a new technology from Leo Cancer Care and a major academic medical center with a track record of cutting-edge technology development and implementation, all working together on behalf of cancer patients."UW Health worked closely with Proton International, a consulting organization dedicated to connecting hospitals and physicians with proton specialists and developing state- of-the-art proton therapy facilities."The team at Proton International is excited to help UW Health bring this important technology to the people of Wisconsin," said Chris Chandler, CEO, Proton International. "We also believe that the Leo Cancer Care's upright treatment room is an important innovation that will help patients and we look forward to working on the project implementation.""We feel privileged that we were selected by UW Health, one of the top healthcare institutions in the nation," said Hiroyuki Itami, General Manager of the Smart Therapy Division of Hitachi. "We are also thrilled to partner with Leo Cancer Care and Proton International to achieve a new innovative proton therapy solution. Hitachi is committed to supporting people's quality of life through technical advancement."UW Health broke ground on Eastpark Medical Center in May and it is expected to open in 2024.(1) Cone beam CT provides three-dimensional anatomical images of patients, at isocenter immediately prior to being treated. Information on the location of bone is obtained from traditional orthogonal x-rays and the motion of tumors is captured by RGPT. These are then combined with the ability to identify healthy tissue surrounding a tumor, particularly the location and shape of soft tissue, via Cone beam CT.(2) RGPT allows real-time beam irradiation to the tumor while compensating for movement associated with respiration. This technology was collaboratively developed between Hokkaido University and Hitachi and supported by the Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST) of the Japan Society for the Promotion of Science. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
TrialWire(TM) 技术平台宣布基于成功的患者招募计划 ACN Newswire

TrialWire(TM) 技术平台宣布基于成功的患者招募计划

July 18, 2022
ADELAIDE, AUS, Jul 18, 2022 - (亚太商讯 via SEAPRWire.com) - TrialWire(TM) 技术平台是由 Salesforce Health Cloud 提供支持的用于试验救援的最快、最安全的数字患者招募平台，今天宣布启动其基于成功的招募计划。随着全球临床预算和投资资金的收紧，TrialWire 正在通过基于成功的患者招募解决方案来支持生物技术药物开发部门。基于成功的计划旨在帮助管理预算，这意味着赞助商仅在某人实际参加研究时才付费。此外，招聘可以在 24 小时内开始，因为该平台不受正常冗长的审批流程的约束。基于成功的计划包括 TrialWire(TM) 技术平台的所有正常收益：- 每位研究协调员都有专用的安全仪表板，他们可以在其中查看患者详细信息和医疗信息- 每个站点有多个仪表板，因此所有研究协调员都可以看到实时进度- 赞助商和 CRO 的仪表板，他们可以在其中查看去识别化的推荐状态信息- 仪表板内的安全 SMS 系统可与患者进行即时通信——预约电话和筛查访问- 自动化 AI 匹配和算法驱动的“查找和筛选”患者流程- 研究协调员的每分钟指标显示在他们的网站上推荐、联系、筛选和注册的人数- 赞助商和 CRO 的每分钟指标，显示研究中所有站点的推荐、联系、筛选和注册人数- HIPAA 合规性和所有患者隐私安全- 基于 Salesforce Health Cloud 构建- 全球无限数量的站点- 提供所有语言版本超过 80% 的临床试验未能按时招募患者，30% 的研究机构无法达到招募目标 - 10% 的机构没有招募任何患者 - TrialWire(TM) 让赞助商及其 CRO 高枕无忧.TrialWire(TM) 非常适合希望避免长期招聘延迟的申办者和 CRO。在此处索取更多信息 https://trial-wire.com/contact/ 在这里了解更多 https://www.trial-wire.com/关于 TrialWire(TM) www.trial-wire.comTrialWire(TM) 是一家私营技术公司，在临床试验患者招募领域拥有 25 年的经验。 TrialWire(TM) 正在解决药物开发领域最严重的问题，其近期估值为 2700 万美元。它的使命是结束患者招募危机，延迟新疗法的开发，由于无法快速找到合适的人并在站点级别招募他们，导致制药公司每天花费数十亿美元。TrialWire(TM) 平台是最安全的服务（由 Salesforce Health Cloud 提供支持），它使用先进的算法来找到可能适合平台上可用研究的合适在线人员。他们被邀请进入平台并通过 AI-Match 筛选器确定与研究的完全匹配——基于站点的或远程/虚拟的。无需注册帐户即可查找和申请研究。该平台从经批准的试验注册中心（如 ClinicalTrials.Gov）中提取研究数据。它使用先进的在线算法根据详细的人口统计和位置资料查找患者/试验匹配。TrialWire(TM) 成功的关键在于它找到了积极在线的人，他们试图更多地了解他们的状况。它们可以在 2 分钟内连接到站点。这些人的保留率很高。与所有其他数字招聘公司不同，TrialWire(TM) 不会在研究完成后保留患者详细信息——没有数据库，因此没有潜在的隐私泄露。赞助商无需为将患者送往其他研究的数据库建设付费。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More

Perfect Medical’s Major Shareholders Further Increase along with Company Buybacks, Strong Confidence in the Future Prospects

July 8, 2022
HONG KONG, Jul 8, 2022 - (ACN Newswire via SEAPRWire.com) - Perfect Medical Health Management Limited ("Perfect Medical" or the "Company", the "Group"; Stock code: 1830.HK), one of the largest medical groups in Hong Kong, together with its subsidiaries (collectively referred to as the "Group"), is pleased to announce that on the 4th and 5th July 2022, Dr. Au-Yeung Kong, the executive director, chairman and chief executive officer of the Group ("Dr. Au-Yeung") further purchase a total of 7,5000,000 shares of the Company, for an aggregate consideration of HK$30.675 million. Following the further purchase, Dr. Au-Yeung is interested in an aggregate of 909,287,383 shares and his equity stake increased from 72.92% to 73.33%. At the same time, on the 4th of July 2022, the Company repurchased 1,000,000 shares for an aggregate consideration of HK$3.978 million under the Repurchase Mandate, representing approximately 0.08% of the issued share capital. The Company announced its FY2021/22 annual results in late June. The Company achieved a historical high revenue of HK$1.35 billion, representing a growth of 23.9% despite the impact of the pandemic. The Company achieved a net profit of HK$305.2 million. If excluding the government subsidies in both years, the revised net profit for the Group increased by 29.8%. With a solid financial position, actively seeking mergers and acquisitions of medical projects and global expansion strategies, the Company will deliver sustainable growth in the long run. Dr. Au-Yeung, said that "the further purchase demonstrates the confidence about the future prospects of the Company and is optimistic about the Company's future development and may consider further increasing the shareholding in the Company when appropriate in the future. With the weakening of the impact of the pandemic, the Company is well-positioned to capitalize on the market opportunities and respond to the rebound of customers' demand in the post-pandemic era. In the future, the Company will gear up its effort organically, actively seek mergers and acquisitions of medical projects, and make optimization and integration to offer additional high-quality services to our customers. Looking ahead, the Company will increase the proportion of medical services and proceed with the international business expansion, with a view to becoming a truly multinational medical group." About Perfect Medical Health Management LimitedPerfect Medical Health Management Limited is a multinational aesthetic medical corporate and one of the largest aesthetic medical companies in Hong Kong established in 2003. The Group focuses primarily on non-invasive aesthetic medical services and medical services in Hong Kong, China, Macau, Australia and Singapore with a total service area spanning approximately 322,000 square feet. Our operation offers a broad spectrum of professional services with assurance of utmost safety and efficacy. The Company was included as a constituent stock of the MSCI Hong Kong Small Cap Index on 27 May 2021, demonstrating the confidence of the capital market and recognizing the investment value of the Company. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
E.Design Insurance and Eisai Enter Into Business Alliance JCN Newswire

E.Design Insurance and Eisai Enter Into Business Alliance

June 28, 2022
TOKYO, Jun 28, 2022 - (JCN Newswire via SEAPRWire.com) - E.design Insurance Co., Ltd., a direct non- life insurance company of the Tokio Marine Group, and Eisai Co., Ltd. announced today that both companies have entered into a business alliance agreement aiming to realize a society where people can safely enjoy driving for a longer period of their lives in anticipation of the advent of super-aging society, under the theme of "Improving Brain Health (brain performance) for Safe Driving." EDSP, as an Insurtech (a term coined by combining insurance and technology) company which promotes "co-creation of a world without accidents" with customers and other companies or local governments, and Eisai, which aims to build a dementia ecosystem through coexisting with various industries and organizations to remove the diverse anxieties of each individual, both will take this business alliance as an opportunity to promote safe driving and extend driving life, thereby contributing to solving the issues associated with an aging society.The initiatives planned under the alliance are as follows.1. Providing an opportunity to check brain healthThe privilege of using "NouKNOW", the digital tool for self-assessment of brain health distributed by Eisai, will be offered to customers who have purchased the "&e", automobile insurance of EDSP (Scheduled for July 2022). With "NouKNOW", brain health is measured quantitatively through a simple card test using smartphone or other devices, evaluating psychomotor function, attention, learning and memory, and working memory. When driving a car, the human brain processes a variety of information, such as road conditions, traffic volume, or the route to a destination, and makes instantaneous judgements repeatedly. Introducing "NouKNOW" is intended to promote safe driving and encourage people to become more aware of their brain health on a daily basis, which is thought to contribute to human judgment while driving.2. Jointly developing solutions for maintaining and improving brain healthEDSP and Eisai will jointly develop solutions that help maintain and improve brain health, by leveraging Eisai's experience and expertise, to enable customers to drive safely for a longer period of time in their lives. Both companies aim to create new solutions, including the development of training contents utilizing data on the characteristics of daily driving behavior and data on brain functions, and the development of a service, targeting customers whose brain health has declined or whose risky behavior has increased, to compile an integrated report on their brain performance and safe driving capability by utilizing the driving score provided by "&e" and the "NouKNOW" score, that allows customers to share the results not only with themselves but also with their families.About "&e"The "&e", co-creation-type auto insurance, provides benefits such as support services for safe driving tailored to each customer by linking IoT sensors and smartphones, in order to reduce the number of customers involved in accidents by even one.For more information about the "&e", please visit www.e-design.net/About "NouKNOWTM""NouKNOW" (non-medical equipment) is a self-checking tool of brain health (brain performance) developed by Eisai based on the algorithm created by Cogstate, Ltd. (Headquarters: Australia) for which Eisai holds the rights for exclusive development and commercialization worldwide. It is not a tool for the prevention and diagnosis of diseases, but therefore for the purpose of self-checking brain performance in order to raise health awareness. This digital tool allows users to self-assess independently evaluating psychomotor function, attention, learning and memory, and working memory in a short time frame (approx.15 minutes) through a simple card test using smartphone or other devices.For more information about "NouKNOW", please visit https://nouknow.jp/ (Japanese only) About E.design Insurance Co., Ltd.E.design Insurance Co., Ltd. is an Insurtech company* of the Tokio Marine Group with the mission of "not only supporting peace of mind in the event of an accident, but also creating a world without accidents, together with our customers." E.design Insurance Co., Ltd. is taking on the challenge of realizing a "world without accidents" through projects such as the "Safe Drive With," a project to reduce accidents using driving data with "&e" and various data on traffic safety, and the "+Machi (Pla-Machi)," a donation program for community-based initiatives to reduce traffic accidents and promote traffic safety, together with customers, local governments, and companies that support our aim of "creating safety through data. E.design Insurance Co., Ltd. will continue to work with its customers to create a new form of insurance industry.*For more information on Insurtech insurer, please see Tokio Marine Holdings, Inc. News Release: bit.ly/3ylN7b0About Eisai Co., Ltd.The Eisai's Corporate Philosophy is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Philosophy (also known as human health care (hhc) philosophy), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. Under the medium-term business plan "EWAY Future & Beyond", which began in April 2021, Eisai is expanding its main role in healthcare, that is, we should contribute not only to people in the medical domain but also to people in the daily living domain. We aim to evolve into an hhceco (hhc philosophy + eco-system) company that empowers people "to realize their fullest life" by creating solutions based on science and data through building an ecosystem in collaboration with other industries.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), with working on various activities together with global partners. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
G20 committed to financing better pandemic response ACN Newswire

G20 committed to financing better pandemic response

June 22, 2022
JAKARTA, Jun 22, 2022 - (ACN Newswire via SEAPRWire.com) - The G20 members and several relevant international organizations agreed to work together to create the Financial Intermediary Fund (FIF) to help countries in need to face any pandemic in the future.Indonesian Health Minister Budi Gunadi Sadikin (L) and Indonesian Finance Minister Sri Mulyani (R) at the first G20 Joint Finance and Health Ministerial Meeting held in Yogyakarta, 21 June. (ANTARA/AstridFaidlatulHabibah)During the 1st G20 Joint Finance and Health Ministerial Meeting held in Yogyakarta on Tuesday, Indonesian Finance Minister Sri Mulyani emphasized the urgency for collaborative work between health and finance sectors to better prepared for future pandemics, considering that the COVID-19 would not be the last."The world is definitely watching us - how the G20 is going to respond with delivering concrete action in pandemic preparedness and response. The world is waiting for us," Mulyani remarked.Furthermore, she also asserted the importance of inclusivity in the work of FIF, led together by the World Health Organization (WHO) and the World Bank, which required the involvement of both developed and developing countries."Only then, we can be effective in preparing to tackle the next global pandemic together," Mulyani stated."I would like to acknowledge the central role of the WHO in fighting pandemic and the importance of including the voice of developing countries in our institutional arrangement to create the most effective system for pandemic preparedness and response," she added.The WHO and the World Bank estimated that US$31 billion is required annually for strengthening global health security, according to WHO Director General Tedros Adhanom Ghebreyesus.About two-third of that fund could come from existing resources but that leaves a gap of US$10 billion per year. Hence, he expects that the FIF would help close that gap.WHO and the World Bank have been cooperating to establish the FIF, which would be overseen by a board that takes a decision on funding allocation supported by a technical advisory panel.Both the board and the technical advisory panel would be supported by the joint WHO-WB secretariat based at the Bank's headquarters in Washington, with assisting staff from the WHO.According to the plan, the Bank will provide financial and administrative leadership at the secretariat, operate as a representative for the FIF, hold and transfer relief funds, as well as provide administrative services.Meanwhile, the WHO will provide technical leadership; coordinate input for the technical advisory panel; and prepare relevant technical documentation, recommendations, and reports for the council.Both the World Bank and WHO will act as implementing entities, along with other global health partners with relevant expertise, including the Global Fund, the Global Alliance for Vaccines and Immunization (GAVI), and the Coalition for Epidemic Preparedness Innovations (CEPI)."We look forward to your active participation in building and financing a FIF that is inclusive, equitable, and effective in making our world safer from pandemics," Tedros noted.To date, the G20 has pushed for an emergency fundraising commitment of around US$1.1 billion from five member countries and one international social organization to mobilize the role of FIF.The pledges came from the United States, the European Union, Germany, Indonesia, Singapore, and the Wellcome Trust.Additionally, Indonesian Health Minister Budi Gunadi Sadikin stated the meeting was not only focusing on the FIF as the source of funds to face future pandemics, but the world must also think about the uses of funds."Because money is (only) half the solution for the health crisis. We need to translate this money into access to vaccines, medicines, and diagnostic tools," he said at a press conference after the joint ministerial meeting.In order to create such access, he explained, the engagement with private sectors as the producers of vaccines, therapeutics, and diagnostics was crucial."We need to talk to them, to engage with them. How can they maintain a certain volume commitment? How then we will be able to distribute equally and very quickly if the next pandemic happens?" he noted.The establishment of FIF is still in the ongoing discussion that will be continued at the next G20 meetings, hosted this year by Indonesia.However, as the G20 President, Indonesia will continue to gather as much as possible support from more countries as well as an international organization even philanthropists, in order for them to be able to contribute to the financing side of pandemic preparedness and response.Written by: Yashinta Difa Pramudyani, Editor: Fardah Assegaf (c) ANTARA 2022 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
SINGAPORE ANNUAL MEETING: DIA and CoRE Gathering Key Healthcare Experts in Neutral Forum to Discuss Regulatory News and Drug Development SeaPRwire

SINGAPORE ANNUAL MEETING: DIA and CoRE Gathering Key Healthcare Experts in Neutral Forum to Discuss Regulatory News and Drug Development

June 15, 2022
From 12-13 July 2022, industry experts and health authorities from Asia-Pacific meet for the 5th time Singapore, June 15, 2022 – (ACN Newswire) – The COVID-19 pandemic has ushered an increased speed of healthcare innovations with the hope of effectively managing this public health threat. This meeting offers a neutrally organized forum to discuss lessons learned and better prepare the healthcare system for the next challenges. From 12-13 July, representatives from Regulatory agencies, health authorities (Ali Al dalaan,[SFDA] Wen-Yi Hung[TFDA] Shin-ichi Okudaira [PMDA]) Jesusa Joyce N. CIRUNAY [Philippines FDA] and industry leaders (Serena Chan [Syneos Health], Daniela Caiazza [Novotech], Ralf Altenburger[Roche], Yu LIANG [MSD], and many more) meet in person for the first time in two years to foster positive changes in the healthcare environment in the Asia-Pacific. That includes emerging technologies, innovations in cancer care, digital health and improved patient access to novel therapies. Sessions discussing Digital Health, Decentralized Clinical Trials, and access to Innovative Therapies Connecting different perspectives and interests in a neutral forum allows an open dialogue and facilitates solutions and concrete action points for today’s healthcare challenges, such as: Fostering digital health adoption in the Asia-Pacific is highly dependent on regulatory frameworks. The session will discuss benefits of digital health, personalised care and what is necessary to improve application in the region. The dynamics of decentralised clinical trials has the potential to improve patients’ experience. Serena Chan (Syneos Health Singapore), Daniela Caiazza (Novotech), and Jerome Armellini (IQVIA Singapore) will discuss how decentralised trials can benefit patients, clinicians, trial sites and sponsors beyond the pandemic setting. Novel approaches for managing cancer come from innovative cell and gene therapies. Challenges arise when it comes to country-specific regulations. Together with other specialists, Ralf Altenburger (Global Head Cell and Gene Therapy, F. Hoffmann La-Roche) will present where the field is going as an integral part of cancer care. Building regulatory agility for improved patient access became more aware throughout the pandemic. Ali Al dalaan (SFDA) will present his view on regulatory convergence and discuss with industry leaders how to improve patient access through regulatory agility. Empowering the ASEAN patients is subject of a townhall format, where all participants wrap up the conference and discuss the efficiency and sustainability of healthcare systems in ASEAN and identify next steps. About DIA Singapore Annual MeetingDate: 12-13 July 2022Location: Grand Copthorne Waterfront Hotel, SingaporeHavelock RoadSingapore 169663Singapore Registration information:Register before the 30th of June and get a 25% discount using the following code: SAM2022– Register online here: https://bit.ly/3aPsB9o– Register with one of our Team member: kanchan.patel@DIAglobal.org About DIA DIA (founded as the Drug Information Association) is a global association that mobilizes life science professionals from across all areas of expertise to engage with patients, peers, and thought leaders in a neutral environment on the issues of today and the possibilities for tomorrow. As a member-driven, volunteer organization, professionals from 80 countries have affected healthcare outcomes, by engaging with DIA through an unparalleled network, educational offerings, and professional development opportunities.DIA is based in Washington, DC (US) with regional offices representing the Americas (Horsham, PA, US); Europe, the Middle East, and Africa, (Basel, Switzerland); and Asia (Beijing and Shanghai, China; Mumbai, India; and Tokyo, Japan). Connect with DIA:Twitter: https://twitter.com/DrugInfoAssnLinkedIn: www.linkedin.com/company/diaFacebook: www.facebook.com/DrugInformationAssociation/Instagram: www.instagram.com/druginfoassn/ About Centre of Regulatory Excellence (CoRE): Launched in 2014, CoRE at Duke-NUS Medical School, is the first dedicated Asian centre targeted at addressing the capacity development and policy innovation needs of national health regulators, the biomedical industry, and pharmaceutical and medical device companies. The Centre provides a neutral academic platform to establish regional platforms and networks to exchange knowledge, encourage innovation, promote thought leadership and collaboration in strengthening regulatory science and policy, and health systems frameworks, within and among national regulatory agencies, industry, health ministries and academia. Contact: CoRESherna WADIAAssociate DirectorCentre of Regulatory ExcellenceDuke-NUS Medical SchoolEmail: core@duke-nus.edu.sg DIAKanchan PATEL,DIA Associate Director, India-Singapore OperationsEmail: kanchan.patel@DIAglobal.org
More